Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Cmax Ratio
研究概览
简要总结
The purpose of this study is to assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine in plasma and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation.
详细描述
An open-label, randomized, two-treatments, three-periods, three-sequences, semi-replicate crossover bioequivalence study with a washout period of at least 14 days between doses. Healthy, mixed skin Arab & Mediterranean Subjects ages between 18 and 50 years, body-mass index 18.5 to 30.0 kg/m2 inclusive (minimum of 50 kg weight), non-smokers or light smokers (smokers of not more than 10 cigarettes per day).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects.
- •Ethnic Group: Arab & Mediterranean.
- •Race: Mixed skin (white & black skin people).
- •Age 18-50 years.
- •Body-mass index 18.5 to 30.0 kg/m2 inclusive. (minimum of 50 kg weight)
- •Subject is available for the whole study period and gave written informed consent.
- •Normal Physical examination.
- •Vital signs within normal ranges.
- •All laboratory screening results within the normal range, or being assessed as clinically Non-significant by the attending physician.
- •Normal Kidney & Liver functions test
排除标准
- •Women of childbearing potential who don't use any contraceptive method, pregnant and/or lactating women.
- •Ethnic Group (Non- Arab &/ or Non- Mediterranean)
- •History of severe allergy or allergic reactions to study drug or related drugs or heparin
- •Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
- •History of serious illness that can impact fate of drugs
- •Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease.
- •Clinically significant illness 4 weeks before study Period I
- •Mental disease.
- •Smoking of more than 10 cigarettes per day
- •The intake of alcohol and grapefruit during the study.
- •The intake of caffeine, xanthenes, or CO2-containing beverages during hospitalization.
- •Regular use of medication.
- •Having taken medication that could affect the investigated drug product: a) Regular consumption of drugs during the two weeks prior to study initiation day, b) consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates, Carbamazepine, Phenytoin, Amphetamine, Benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine and methadone) during one month before the study initiation.
- •Presence of any significant physical or organ abnormality
- •Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14 days before study Period I
- •Participation in another bioequivalence study and/or Clinical trials within 80 days prior to the start of this study Period I
- •Following a special diet (e.g. vegetarian) or dieting one month before the study initiation.
- •Subjects with seizures or prior history of seizures.
- •Prior history of hypersensitivity to dirithromycin, erythromycin, or other macrolide antibiotics
- •Any significant clinical abnormality including HBsAg, HCV, and / or HIV.
- •Consumption of grapefruit or grapefruit containing products within 7 days of drug administration
- •Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
- •Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent significant change in dietary or exercise habits.
- •Subjects with history of Liver disease.
- •Abnormal Vital Signs.
- •Abnormal Kidney and/or Liver functions test.
- •Vomiting, Diarrhea on admission
研究组 & 干预措施
DYNABAC 250 MG ENTERIC COATED TABLET
DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
干预措施: DYNABAC 250 MG ENTERIC COATED TABLET (Drug)
DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
干预措施: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET (Drug)
结局指标
主要结局
Cmax Ratio
时间窗: pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing.
Scaled average bioequivalence will be performed. Bioequivalence limits will be defined and widened according to the reference variance of σw2 within subject variability for the reference for Erythromycylamine.
AUC Ratio
时间窗: pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing
The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00%based on Erythromycylamine
次要结局
未报告次要终点